WHITEHOUSE STATION, N.J. —
Merck & Co., a Dow component and the world’s second-biggest drugmaker by revenue, will be touting recent product launches and encouraging data on some important experimental medicines when it reports its third-quarter results before the stock market opens Friday.
WHAT TO WATCH FOR: Executives will note the recent launches of three new products in some markets: Dulera, for asthma, in the U.S.; Daxas, for chronic lung disorders, in various countries outside the U.S., and Brinavess, for an irregular heartbeat called atrial fibrillation, in the European Union, Iceland and Norway.
Merck will discuss mid-stage results presented last week on osteoporosis drug odanacatib, which is now in the midst of a 16,000-patient, late-stage study. It likely will note that data on other key drugs is coming shortly.
….Executives may also mention that Merck expects U.S. regulators by year’s end to approve or reject two new uses for its vaccine against cervical cancer and genital warts, Gardasil. One is for anal cancer, and the other is for women aged 27 to 45. Gardasil now is approved for girls and women up to age 26.